Intuitive Surgical, Inc. $ISRG Shares Acquired by UNIVEST FINANCIAL Corp

UNIVEST FINANCIAL Corp raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 16.1% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 13,113 shares of the medical equipment provider’s stock after acquiring an additional 1,822 shares during the period. UNIVEST FINANCIAL Corp’s holdings in Intuitive Surgical were worth $5,332,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in ISRG. Bank of New York Mellon Corp bought a new position in Intuitive Surgical in the 2nd quarter valued at $1,335,753,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Intuitive Surgical by 95.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider’s stock valued at $970,635,000 after purchasing an additional 1,027,475 shares during the period. Assenagon Asset Management S.A. increased its position in shares of Intuitive Surgical by 55.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,557,940 shares of the medical equipment provider’s stock valued at $633,505,000 after buying an additional 558,099 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Intuitive Surgical during the 3rd quarter valued at $136,743,000. Finally, Amundi increased its stake in Intuitive Surgical by 8.6% in the 1st quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock worth $1,119,448,000 after acquiring an additional 193,096 shares during the last quarter. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Stock Performance

ISRG stock opened at $449.53 on Thursday. The company has a market capitalization of $155.83 billion, a PE ratio of 54.36, a price-to-earnings-growth ratio of 3.10 and a beta of 1.45. Intuitive Surgical, Inc. has a one year low of $328.57 and a one year high of $603.88. The company’s 50 day moving average price is $414.76 and its two-hundred day moving average price is $430.83.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.35. The company had revenue of $3.05 billion for the quarter, compared to analysts’ expectations of $2.91 billion. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The firm’s revenue was up 21.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.40 EPS. On average, research analysts predict that Intuitive Surgical, Inc. will post 9.37 EPS for the current year.

Insider Activity

In other news, SVP Patricia Wadors sold 1,078 shares of the firm’s stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $443.80, for a total transaction of $478,416.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Craig Barratt sold 1,150 shares of Intuitive Surgical stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $443.80, for a total value of $510,370.00. Following the completion of the transaction, the director owned 1,150 shares in the company, valued at approximately $510,370. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 39,056 shares of company stock valued at $17,585,864. Company insiders own 0.60% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on ISRG. Leerink Partners set a $503.00 price objective on Intuitive Surgical and gave the stock an “outperform” rating in a report on Wednesday, October 21st. Barclays reaffirmed an “overweight” rating and issued a $500.00 target price (up from $485.00) on shares of Intuitive Surgical in a research note on Wednesday, October 21st. Stifel Nicolaus dropped their target price on shares of Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating for the company in a research report on Friday, July 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Intuitive Surgical in a research report on Friday, August 14th. Finally, BTIG Research reissued a “buy” rating and issued a $454.00 price target on shares of Intuitive Surgical in a research note on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $493.54.

Intuitive Surgical Company Profile

Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.